United Therapeutics (UTHR) stock plummeted 6.85% in the pre-market trading session on Wednesday, following the company's fourth-quarter 2024 earnings report that missed analysts' estimates on profit despite strong revenue growth.
The biopharmaceutical company reported earnings of $6.19 per diluted share for the quarter ended December 31, 2024, missing the analyst consensus estimate of $6.27 by 1.28%. However, United Therapeutics posted revenue of $735.9 million, beating expectations of $734.7 million.
While the company's revenue grew by nearly 20% year-over-year, driven by strong sales of its lung disorder inhaled-drug Tyvaso, investors appeared disappointed with the earnings miss. According to analysts, the seasonal trends in Tyvaso sales were not as robust as expected during the quarter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.